암 면역치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Cancer Immunotherapy Market size is expected to reach USD 436.18 Billion in 2034 from USD 116.13 Billion (2025) growing at a CAGR of 15.84% during 2026-2034.

The Global Cancer Immunotherapy Market is experiencing rapid growth as innovative treatments transform cancer care. Immunotherapy harnesses the body's immune system to target and destroy cancer cells, offering improved survival rates and fewer side effects compared to traditional therapies. Rising cancer prevalence worldwide and increasing awareness about advanced treatment options are key growth drivers for the market.

Significant investments in research and development are accelerating the introduction of novel therapies such as checkpoint inhibitors, CAR-T cell therapies, and monoclonal antibodies. Pharmaceutical companies are collaborating with research institutions to develop personalized treatment approaches. Regulatory approvals for new immunotherapy drugs are also contributing to expanding market availability across major healthcare markets.

Future prospects remain highly promising as precision medicine and biomarker-based therapies gain traction. Technological advancements and expanding clinical trials are expected to broaden treatment applications across multiple cancer types. Growing healthcare expenditure and supportive government initiatives will likely continue driving the global cancer immunotherapy market toward sustained growth in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Type

• Checkpoint Inhibitors
• Monoclonal Antibodies
• Vaccines
• Cell Therapies
• Immunomodulators
• Oncolytic Virus

By Application

• Lung Cancer
• Breast Cancer
• Melanoma
• Multiple Myeloma
• Prostate Cancer
• Ovarian Cancer
• Cervical Cancer
• Stomach Cancer
• Colorectal Cancer
• Head & Neck Cancer
• Others

By End User

• Hospitals
• Oncology Clinics
• Homecare
• Others

By Form

• Intravenous (IV)
• Intramuscular
• Oral

By Distribution Channel

• Direct Tenders
• Retail Sales
• Pharmacies

COMPANIES PROFILED

• Merck Co Inc, F HoffmannLa Roche Ltd, BristolMyers Squibb Company, Janssen Pharmaceutical, AstraZeneca, Gilead Sciences Inc, Lilly, Amgen Inc, Novartis AG, GSK plc, Pfizer Inc, AbbVie Inc, Bayer AG, BioNTech SE, Moderna Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER IMMUNOTHERAPY MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. Checkpoint Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Cell Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Immunomodulators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Oncolytic Virus Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER IMMUNOTHERAPY MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Melanoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Multiple Myeloma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Ovarian Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Cervical Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Stomach Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.10. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.11. Head & Neck Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.12. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER IMMUNOTHERAPY MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Oncology Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANCER IMMUNOTHERAPY MARKET: BY FORM 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Form
• 7.2. Intravenous (IV) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Intramuscular Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CANCER IMMUNOTHERAPY MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Direct Tenders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Retail Sales Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL CANCER IMMUNOTHERAPY MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Product Type
  • 9.2.2 By Application
  • 9.2.3 By End User
  • 9.2.4 By Form
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Product Type
  • 9.3.2 By Application
  • 9.3.3 By End User
  • 9.3.4 By Form
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Product Type
  • 9.4.2 By Application
  • 9.4.3 By End User
  • 9.4.4 By Form
  • 9.4.5 By Distribution Channel
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Product Type
  • 9.5.2 By Application
  • 9.5.3 By End User
  • 9.5.4 By Form
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Product Type
  • 9.6.2 By Application
  • 9.6.3 By End User
  • 9.6.4 By Form
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL CANCER IMMUNOTHERAPY INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Merck & Co. Inc
  • 11.2.2 F. Hoffmann-La Roche Ltd
  • 11.2.3 Bristol-Myers Squibb Company
  • 11.2.4 Janssen Pharmaceutical
  • 11.2.5 AstraZeneca
  • 11.2.6 Gilead Sciences Inc
  • 11.2.7 Lilly
  • 11.2.8 Amgen Inc
  • 11.2.9 Novartis AG
  • 11.2.10 GSK Plc
  • 11.2.11 Pfizer Inc
  • 11.2.12 AbbVie Inc
  • 11.2.13 Bayer AG
  • 11.2.14 BioNTech SE
  • 11.2.15 Moderna Inc